Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

Lindor, Keith D., Kowdley, Kris V., Heathcote, Jenny E., Harrison, Edwyn M., Jorgensen, Roberta, Angulo, Paul, Lymp, James F., Burgart, Lawrence +1 more·2004·Hepatology
DOI 10.1002/hep.20092

Cited by (727)

Items 201–300 of 727

  1. Primary hepatocellular carcinoma and metabolic syndrome: An update
    Rubayat N. Rahman · 2013 · World Journal of Gastrointestinal Oncology
  2. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
    Hyejin Yoon · 2014 · World Journal of Hepatology
  3. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
    Rosa Lombardi, Simona Onali, Douglas Thorburn, Brian Ritchie Davidson, Kurinchi Selvan Gurusamy, Emmanuel A. Tsochatzis · 2017 · Cochrane Database of Systematic Reviews
  4. A critical review of endpoints for non-cirrhotic NASH therapeutic trials
    Ratziu, Vlad · 2018 · Journal of Hepatology
  5. Probiotics and Nonalcoholic Fatty liver Disease.
    Tannaz Eslamparast, Sareh Eghtesad, Azita Hekmatdoost, Hossein Poustchi · 2013 · Europe PMC (PubMed Central)
  6. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Byung‐Wan Lee, Yong‐ho Lee, Cheol‐Young Park, Eun‐Jung Rhee, Won‐Young Lee, Nan Hee Kim, Kyung Mook Choi, Keun‐Gyu Park, Yeon‐Kyung Choi, Bong Soo et al. · 2020 · Diabetes & Metabolism Journal
  7. How should we manage patients with non‐alcoholic fatty liver disease in 2007?
    Henry Lik‐Yuen Chan, H Janaka de Silva, Nancy W.Y. Leung, Seng Gee Lim, Geoffrey C. Farrell, the Asia–Pacific Working Party on NAFLD · 2007 · Journal of Gastroenterology and Hepatology
  8. Hepatic Complications of Obesity
    Anna Mae Diehl · 2010 · Gastroenterology Clinics of North America
  9. Animal models for the study of liver fibrosis: new insights from knockout mouse models
    Hiromitsu Hayashi, Takao Sakai · 2011 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  10. Orlistat Reverse Fatty Infiltration and Improves Hepatic Fibrosis in Obese Patients with Nonalcoholic Steatohepatitis (NASH)
    Osamah Hussein, Maria Grosovski, Sorina Schlesinger, Sergio Szvalb, Nimer Assy · 2007 · Digestive Diseases and Sciences
  11. Hypertension and fatty liver: guilty by association?
    Matthew Brookes, Brian T. Cooper · 2007 · Journal of Human Hypertension
  12. Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability
    Vlad Ratziu, Elisabetta Bugianesi, John B. Dixon, E Fassio, Mattias Ekstedt, Frédéric Charlotte, Stergios Kechagias, Thierry Poynard, Rolf Olsson · 2007 · Alimentary Pharmacology & Therapeutics
  13. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
    Moon Young Kim, Mee-Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon et al. · 2012 · Liver International
  14. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis
    Ayako Suzuki, James F. Lymp, Jennifer L. St. Sauver, Paul Angulo, Keith D. Lindor · 2006 · Liver International
  15. Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
    Ng, Cheng Han, Xiao, Jieling, Lim, Wen Hui, Chin, Yip Han, Yong, Jie Ning, Tan, Darren Jun Hao, Tay, Phoebe, Syn, Nicholas, Foo, Roger, Chan, Mark et al. · 2022 · Hepatology
  16. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions
    Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny, Ebtehal El‐Demerdash · 2021 · Life Sciences
  17. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results
    Florence Juget Pietu, Olivier Guillaud, Thomas Walter, Mélanie Vallin, Valérie Hervieu, Jean‐Yves Scoazec, Jérôme Dumortier · 2011 · Clinics and Research in Hepatology and Gastroenterology
  18. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH
    Adriana Carino, Michele Biagioli, Silvia Marchianò, Chiara Fiorucci, Angela Zampella, Maria Chiara Monti, Paolo Tommaso Scarpelli, Patrizia Ricci, Eleonora Distrutti, Stefano Fiorucci · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  19. Nonalcoholic Fatty Liver Disease
    Angelo H. Paredes, Dawn McDowell Torres, Stephen A. Harrison · 2012 · Clinics in Liver Disease
  20. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
    Newaz Hossain, Pushpjeet Kanwar, Smruti Ranjan Mohanty · 2016 · Gastroenterology Research and Practice
  21. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial
    Nahúm Méndez‐Sánchez, V. González Fernández, Norberto Carlos Chávez-Tapia, Martha Helena Ramos, Misael Uribe · 2004 · Annals of Hepatology
  22. Pediatric Nonalcoholic Fatty Liver Disease
    Molly A. Bozic, Girish C. Subbarao, Jean Pappas Molleston · 2013 · Nutrition in Clinical Practice
  23. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis
    Maryam Mahjoubin‐Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen Lawrence Atkin, Christos Socrates Mantzoros, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2020 · Molecular Metabolism
  24. Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Melanie D. Beaton · 2012 · Canadian Journal of Gastroenterology
  25. Nonalcoholic Fatty Liver Disease and Obesity
    Sherif N. Saadeh · 2007 · Nutrition in Clinical Practice
  26. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis
    Thomas Greuter, Harmeet Malhi, Gregory James Gores, Vijay H. Shah · 2017 · JCI Insight
  27. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
    Juan Pablo Arab · 2014 · World Journal of Gastroenterology
  28. Pathological features of NASH.
    Elizabeth M Brunt, Dina G Tiniakos · 2005 · PubMed
  29. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic implications.
    Craita Isabela Andronescu, Monica Roxana Purcarea, Petru Aurel Babeș · 2018 · Europe PMC (PubMed Central)
  30. Identification and treatment of metabolic complications in pediatric obesity
    Katie Larson Ode, Brigitte I. Frohnert, Brandon M. Nathan · 2009 · Reviews in Endocrine and Metabolic Disorders
  31. Review article: drug therapy for non‐alcoholic fatty liver disease
    Kevin M. Comar, Richard K. Sterling · 2005 · Alimentary Pharmacology & Therapeutics
  32. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
    Detlef Schuppan, Mark D. Gorrell, Thomas Klein, Michael Mark, Nezam H. Afdhal · 2009 · Liver International
  33. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?
    Amedeo Lonardo, Stefano Bellentani, Vlad Ratziu, Paola Loria · 2011 · Expert Review of Gastroenterology & Hepatology
  34. Treatment strategies in nonalcoholic fatty liver disease
    Herbert Tilg, Arthur Kaser · 2005 · Nature Clinical Practice Gastroenterology &#38 Hepatology
  35. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France
    Vlad Ratziu, Jean–François Cadranel, Lawrence Serfaty, Jacques Denis, Christophe Renou, Patrick Delasalle, Carole Bernhardt, Gabriel Perlemuter · 2012 · Journal of Hepatology
  36. Nonalcoholic Fatty Liver Disease: A Practical Approach to Evaluation and Management
    Nila Rafiq, Zobair M. Younossi · 2009 · Clinics in Liver Disease
  37. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin
    Wuwen Feng, Shuang-yu Kuang, Can Tu, Zhijie Ma, Jing-yao Pang, Yan-hui Wang, Qingce Zang, Ta-si Liu, Yanling Zhao, Xiaohe Xiao et al. · 2018 · Biomedicine & Pharmacotherapy
  38. Interferon gamma‐1b for the treatment of fibrosis in chronic hepatitis C infection
    Andrew Joseph Muir, Pamela B. Sylvestre, Don C. Rockey · 2006 · Journal of Viral Hepatitis
  39. Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome
    Robert S. Rahimi, Carmen E. Landaverde · 2013 · Nutrition in Clinical Practice
  40. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease
    Caihua Wang, Chunpeng Zhu, Liming Shao, Jun Ye, Yimin Shen, Yuezhong Ren · 2019 · Mediators of Inflammation
  41. Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment
    Uk-Il Ju, Do‐Won Jeong, Jieun Seo, Jun Bum Park, Jong‐Wan Park, Kyung‐Suk Suh, Jae Bum Kim, Yang‐Sook Chun · 2020 · Cell Death and Disease
  42. Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD)
    Ratree Sawangjit, Bunchai Chongmelaxme, Pochamana Phisalprapa, Surasak Saokaew, Ammarin Thakkinstian, Kris V. Kowdley, Nathorn Chaiyakunapruk · 2016 · Medicine
  43. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment
    Elisabetta Bugianesi, Rebecca Marzocchi, Nicola Villanova, Giulio Marchesini · 2004 · Best Practice & Research Clinical Gastroenterology
  44. NAFLD leads to liver cancer: Do we have sufficient evidence?
    Xiaoyan Duan, Lei Zhang, Jian‐Gao Fan, Liang Qiao · 2013 · Cancer Letters
  45. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment
    Pasquale Agosti, Carlo Sabbà, Antonio Mazzocca · 2017 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  46. Pharmacological agents for NASH
    Vlad Ratziu · 2013 · Nature Reviews Gastroenterology & Hepatology
  47. Changes in Hepatic Gene Expression upon Oral Administration of Taurine-Conjugated Ursodeoxycholic Acid in ob/ob Mice
    Jae‐Seong Yang, Jin Taek Kim, Jouhyun Jeon, Ho Seon Park, Gyeong Hoon Kang, Kyong Soo Park, Hong Kyu Lee, Sanguk Kim, Young Min Cho · 2010 · PLoS ONE
  48. Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis.
    Metin Başaranoğlu, Brent A. Neuschwander‐Tetri · 2006 · PubMed Central
  49. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
    Angelo Armandi, Elisabetta Bugianesi · 2024 · European Journal of Internal Medicine
  50. Non-alcoholic fatty liver disease
    Einar Stefan Bjornsson, Paul Angulo · 2007 · Scandinavian Journal of Gastroenterology
  51. Nonalcoholic Fatty Liver Disease
    Marcos E. Alfie, William R. Treem · 2006 · Pediatric Annals
  52. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis
    Hayato Nakagawa · 2015 · World Journal of Hepatology
  53. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis
    Rocco Orlando, Lorenzo Azzalini, Serena Orando, Flavio Lirussi · 2007 · Cochrane Database of Systematic Reviews · Retracted
  54. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations
    John W. Richard, Ildiko Lingvay · 2011 · Expert Review of Cardiovascular Therapy
  55. Future therapy for non‐alcoholic fatty liver disease
    Danny Issa, Vaishali A. Patel, Arun Jayant Sanyal · 2018 · Liver International
  56. Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
    Mithun Sharma, Madhumita Premkumar, Anand V. Kulkarni, Pramod Kumar, D. Nageshwar Reddy, Nagaraja Padaki Rao · 2020 · Journal of Clinical and Translational Hepatology
  57. The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease
    Phunchai Charatcharoenwitthaya, Keith D. Lindor, Paul Angulo · 2012 · Digestive Diseases and Sciences
  58. Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology
    Yoshihisa Takahashi · 2010 · World Journal of Gastroenterology
  59. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
    Stuart McPherson, Nina Wilkinson, DINA G. TINIAKOS, Jennifer S. Wilkinson, Alastair D. Burt, Elaine McColl, Deborah D. Stocken, Nick D. Steen, Jane A. Barnes, Nicola Goudie et al. · 2017 · PLoS ONE
  60. Nonalcoholic steatohepatitis
    Brian P. Mulhall, Zobair M. Younossi · 2004 · Current Treatment Options in Gastroenterology
  61. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice
    Hyeon-Soo Jeong, Kang‐Hoon Kim, In‐Seung Lee, Ji Young Park, Yumi Kim, Ki‐Suk Kim, Hyeung-Jin Jang · 2017 · Biomedicine & Pharmacotherapy
  62. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
    Kyung‐Soo Kim, Byung‐Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong Soo, Cheol‐Young Park · 2019 · Diabetes & Metabolism Journal
  63. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas
    Yao-Chi Liu · 2006 · World Journal of Gastroenterology
  64. PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME AND ITS CORRELATION WITH METABOLIC SYNDROME
    Mariana Drechmer Romanowski, Mônica Beatriz Parolin, Alexandre Coutinho Teixeira de Freitas, Mauri José Piazza, Jorgete BASSO, Almir Antônio Urbanetz · 2015 · Arquivos de Gastroenterologia
  65. The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
    Zhonglin Li, Hang Yuan, Huikuan Chu, Ling Yang · 2023 · Microorganisms
  66. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis
    Michael Charlton · 2013 · Current Opinion in Organ Transplantation
  67. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
    Matthew James Armstrong, Darren Barton, Piers Gaunt, Diana Hull, Kathy Guo, Deborah D. Stocken, Stephen C. L. Gough, Jeremy Tomlinson, Rachel Mary Brown, Stefan G. Hübscher et al. · 2013 · BMJ Open
  68. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options
    Bubu A. Banini, Arun Jayant Sanyal · 2016 · Clinical Medicine Insights Therapeutics
  69. Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?
    Esquivel, Carlos Martin, Garcia, Manuel, Armando, Lucas, Ortiz, Guillermo, Lascano, Fernando Martínez, Foscarini, José María · 2018 · Obesity Surgery
  70. The Multifaceted Associations of Hepatobiliary Disease and Diabetes
    David S.H. Bell, Eric Allbright · 2007 · Endocrine Practice
  71. Bile salt–phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent #
    Waleé Chamulitrat, Jürgen Burhenne, Tobias Rehlen, Anita Pathil, Wolfgang Stremmel · 2009 · Hepatology
  72. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?
    Bülent Baran · 2014 · World Journal of Gastroenterology
  73. Mechanisms inactivating the gene for E-cadherin in sporadic gastric carcinomas
    Yao‐Chi Liu, Chen‐Yang Shen, Hurng‐Sheng Wu, Tsai‐Yuan Hsieh, De‐Chuan Chan, Cheng‐Jueng Chen, Jyh‐Cherng Yu, Cheng‐Ping Yu, Horng‐Jyh Harn, Peng‐Jen Chen et al. · 2006 · World Journal of Gastroenterology
  74. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
    Igor Veniaminovich Maev, Aleksey A. Samsonov, Liudmila K Palgova, Chavdar S Pavlov, Elena N. Shirokova, Вовк Елена Ивановна, Kirill M Starostin · 2020 · BMJ Open Gastroenterology
  75. Second World Congress on the Insulin Resistance Syndrome
    Zachary T. Bloomgarden · 2005 · Diabetes Care
  76. Berberine prevents NAFLD and HCC by modulating metabolic disorders.
    Xinyue Lin, Juan-Hong Zhang, Yajun Chu, Qiu-Ying Nie, Jun-Min Zhang · 2024 · Pharmacology and Therapeutics
  77. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
    Michael A Trauner, Emina Halilbasic, Thierry Claudel, Daniel Steinacher, Claudia Daniela Fuchs, Tarek Moustafa, Marion Julia Pollheimer, Elisabeth Krones, Christian Kienbacher, Stefan Traussnigg et al. · 2015 · Digestive Diseases
  78. Novel treatment modalities for nonalcoholic steatohepatitis
    Sanjaya Kumar Satapathy, Arun Jayant Sanyal · 2010 · Trends in Endocrinology and Metabolism
  79. Current and Emerging Therapies in Nonalcoholic Fatty Liver Disease
    M. Kashi, D. Torres, Stephen D. Harrison · 2008 · Seminars in liver disease (Print)
  80. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
    Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim · 2020 · Clinical and Molecular Hepatology
  81. Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials
    Rohit Seth Loomba, ROBERT A. WESLEY, Frank Pucino, T. Jake Liang, David Erwin Kleiner, Joel E. Lavine · 2008 · Clinical Gastroenterology and Hepatology
  82. Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models
    Franck Chiappini, Christophe Desterke, Justine Bertrand‐Michel, Catherine Guettier, François Le Naour · 2016 · Scientific Reports
  83. Present and future therapeutic strategies in non-alcoholic fatty liver disease
    Giuseppe Calamita, Piero Portincasa · 2007 · Expert Opinion on Therapeutic Targets
  84. Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats
    You‐Cheol Hwang, Da-Hee Oh, Moon Chan Choi, Sang Yeoul Lee, Kyu Jeung Ahn, Ho-Yeon Chung, Sung‐Jig Lim, Sung Hyun Chung, In‐Kyung Jeong · 2017 · The Korean Journal of Internal Medicine
  85. Current and future treatment options in non-alcoholic steatohepatitis (NASH)
    Nikolaos Lazaridis, Emmanuel A. Tsochatzis · 2017 · Expert Review of Gastroenterology & Hepatology
  86. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center
    Swastik Agrawal, Ajay Kumar. Duseja, Ashutosh N. Aggarwal, Ashim Das, Manu Mehta, Radha Krishan Dhiman, Yogesh Kumar Chawla · 2015 · Hepatology International
  87. Treatment regimens for non-alcoholic fatty liver disease
    Brian P Lam, Zobair M. Younossi · 2009 · Annals of Hepatology
  88. Review of Treatment Options for Nonalcoholic Fatty Liver Disease
    Richele Corrado, Dawn McDowell Torres, Stephen A. Harrison · 2013 · Medical Clinics of North America
  89. Vitamin D supplementation improves serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A randomized, double-blind, placebo-controlled study
    Piyawat Komolmit, Sayamon Kimtrakool, Sirinporn Suksawatamnuay, Kessarin Thanapirom, Kanita Chattrasophon, Panarat M. Thaimai, Chintana Chirathaworn, Yong Poovorawan · 2017 · Scientific Reports
  90. Consenso mexicano de la enfermedad por hígado graso no alcohólico
    Raúl Bernal-Reyes, Graciela Castro‐Narro, René Malé-Velázquez, Ramón Carmona-Sánchez, M.S. González-Huezo, Ignacio García-Juárez, Norberto Carlos Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia et al. · 2019 · Revista de Gastroenterología de México
  91. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease
    Jue Wei, Dekai Qiu, Xiong Ma · 2009 · Journal of Digestive Diseases
  92. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging
    Lisa K. Koch, Matthew M. Yeh · 2018 · Annals of Diagnostic Pathology
  93. MANAGEMENT OF ENDOCRINE DISEASE: Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease
    Merel M. Ruissen, Anne Linde Mak, Ulrich H. Beuers, Maarten E. Tushuizen, Adriaan Georgius Holleboom · 2020 · European Journal of Endocrinology
  94. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges
    Jia Xiao, Rui Guo, Man‐Lung Fung, Emily C. Liong, George Lim Tipoe · 2013 · Hepatobiliary & pancreatic diseases international
  95. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease
    Alessandro Federico · 2014 · World Journal of Gastroenterology
  96. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review
    Sarah Lindback, Charles C. Gabbert, B. Lamar Johnson, Emmanuil Smorodinsky, Claude B. Sirlin, Natalie C. Garcia, Perrie E. Pardee, Kristin D. Kistler, Jeffrey B. Schwimmer · 2010 · Advances in Pediatrics
  97. Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?
    Mauro Maurantonio, Stefano Ballestri, Maria Rosaria Odoardi, Amedeo Lonardo, Paola Loria · 2011 · Archives of Medical Research
  98. Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease
    Susanne Kaser, Christoph F. Ebenbichler, Herbert Tilg · 2010 · International Journal of Clinical Practice
  99. Ursodeoxycholic Acid Alters Bile Acid and Fatty Acid Profiles in a Mouse Model of Diet-Induced Obesity
    Yunjing Zhang, Xiaojiao Zheng, Fengjie Huang, Aihua Zhao, Kun Ge, Qing Zhao, Wei Ping Jia · 2019 · Frontiers in Pharmacology
  100. Hepatic Fibrosis and Cirrhosis
    Don C. Rockey · 2015 · Wiley eBooks